The NIH Funding Delay That No Top-Line Number Can Show

The Number That Misleads

The National Institutes of Health has a $47.5 billion budget. Congress preserved it. The top line looks unchanged. If you only read the headline, you would assume the American research enterprise is operating as usual.

It is not.

What has shifted is not the amount of money — it is the plumbing. Since the Trump administration took office in 2025, the process of turning appropriated funds into actual grant awards has slowed to a crawl. Through early July 2026, the NIH was running roughly 42 days behind the pace seen between 2021 and 2024. By mid-July, when the agency should have obligated three-quarters of its annual budget, it had committed only about half.

Those billions sitting on the table are not theoretical. They are salaries for lab technicians. Equipment orders for clinical trials. Continuation payments that keep multi-year research projects from imploding mid-cycle. And the delays are not getting shorter — they are becoming structural.

A Black Hole in the Pipeline

Jennifer Troyer knows the inside of the NIH grant machine. She directed extramural operations at the National Human Genome Research Institute until she resigned at the end of 2025, having overseen the disbursement of billions in awards. What she encountered in her final months was something even she did not recognize.

Grants at the NIH move through a series of statuses during review and award preparation. Troyer discovered Status 19 — a processing stage she had never heard of despite years of responsibility for grant management. Awards that had been signed would resurface later, halted and flagged by the Department of Health and Human Services, the Office of Management and Budget, or directly by the White House, marked “not acceptable” for reasons unclear to the staff processing them.

At first, the filtering was done by the Department of Government Efficiency, a Trump-affiliated entity whose involvement was widely reported. When DOGE moved on, the infrastructure it left behind remained. A parallel system of review took its place, and the staffing to operate it did not.

Troyer’s institute went from 11 grants-management specialists and two assistants down to three specialists. There simply were not enough people to push awards through the door. “We did not have the person-time to put awards out the door,” she said.

This is not a temporary bottleneck. It is a reconfiguration of how scientific funding flows from Congress to the laboratory bench — and who gets to decide what reaches it.

When Timing Becomes the Variable

For most of the modern history of the NIH, grant renewals arrived early. A week early, typically. That buffer existed for a reason: biomedical research runs on multi-year commitments, and a gap between renewals means a lab goes dark, a clinical trial pauses, a postdoc’s visa expires.

That convention has disappeared.

In fiscal year 2025, grants were renewed 90 or more days late at a rate of 3.9 percent. In fiscal year 2026, it was 2.7 percent. By comparison, the same lateness rate during the four prior years averaged just 0.7 percent. Ryan Gutenkunst, a professor and department head at the University of Arizona, watched his own renewal stall for two and a half months. He spent that time calculating which staff members he would have to lay off. His university provided bridge funding — but those funds carry a hard 90-day limit. Beyond that, institutions grow reluctant to lend. The risk becomes too great.

The delays cut across party lines and geography. In Democratic-leaning congressional districts, renewal timing shifted from an average of 3.4 days early to 8.4 days late. In Republican districts, it moved from 3.8 days early to 8.0 days late. This is not a regional problem. It is systemic.

Who Pays the Price

The funding reallocation tells a story the delays alone do not.

Research focused on racial and ethnic minority health lost more than $1 billion in 2025 compared to 2024 — a 29 percent decline. AI and machine learning research gained $468 million. Networking and information technology research gained $368 million. These shifts mirror the administration’s stated priorities: executive orders directing agencies to dismantle what it terms “radical” and “wasteful” diversity, equity and inclusion programs, and an August 2025 NIH funding strategy naming AI as a priority area.

But the mechanism of change has drawn concern even from some who support the policy direction. According to a Nature report, a list of disfavored terms — including “climate change,” “DEI,” “gender” and “vaccine hesitancy” — began appearing in grant reviews. Troyer estimated that roughly half of awards required renegotiation, with institutions, principal investigators and program directors agreeing to revised language in titles, abstracts and public-facing materials.

Mariana Stern, a professor at the University of Southern California, experienced this directly. Her research center, formerly the CaRE2 Health Equity Center, had to drop the word “equity” from its name. The research itself remained, but the framing did not.

Scarlett Lin Gomez at the University of California, San Francisco, saw her Greater Bay Area Cancer Registry funding fall from $5.4 million in 2024 to $4.4 million in 2025 to $3.7 million in 2026. She let go seven employees last year and expects to lose five or six more this year. “We’ve not had a cut of this magnitude at all — by far,” she said.

The Brain Drain Is Real

The most consequential effect may not be the research that was cancelled or delayed. It may be the researchers who are leaving.

Students and early-career scientists are watching. Stern noted that an increasing number are hesitant to enter academia, choosing industry instead — where funding is less precarious and compensation is better. Gomez described the trend as accelerating a preexisting “academic brain drain.” The pipeline that has historically supplied the world’s biomedical workforce is narrowing, and the disruption is political rather than merit-based.

This matters beyond the United States. The NIH has been the single largest funder of basic biomedical research in the world for decades. Its grants do not only support American laboratories. They anchor collaborative networks that span Europe, Asia and Africa. Clinical trial infrastructure built on NIH funding has been central to vaccine development, pandemic response and the study of diseases that disproportionately affect low- and middle-income countries. When the NIH slows, the global research ecosystem slows with it.

The International Readout

Other governments have noticed. China’s Ministry of Science and Technology has publicly positioned itself as a stabilizer of scientific cooperation even as U.S.-China research ties have faced political headwinds. European funding bodies, particularly the European Research Council, have quietly expanded their recruitment outreach targeting American postdocs and principal investigators frustrated by domestic uncertainty. Japan’s科学技术政策革新機構 has increased its international fellowship slots.

None of these moves are overtly competitive in the way trade policy is. They are incremental — but compounding. A research group that loses two years of NIH funding may consolidate in a European lab. A doctoral student who defects to industry today will not return. The cumulative effect is a gradual redistribution of scientific gravity that no budget figure captures.

What Comes Next

The most consequential policy development may not have generated much public attention yet. The White House Office of Management and Budget has proposed a rule that, if implemented, would give political appointees the final say on federal grantmaking decisions. Scientists describe it as the institutionalization of the Status 19 phenomenon — a formal channel for executive oversight of what has historically been a peer-reviewed process.

Not everyone sees a problem. Ian Banks, who directs science and development at the Foundation for American Innovation and has advised the White House on science policy, argued that the NIH was overdue for reform. He cited a 2018 survey showing that over 44 percent of principal investigators’ time was consumed by non-research activities, a figure he believes has risen since. He raised the question of whether alternative allocation methods — even a lottery system — might serve science better than the current peer-review model.

Ryan Gutenkunst agreed that the funding debate should be open. “It shouldn’t be a hidden list of words that is dictating things,” he said. “It should be a real discussion between the administration, the scientists and the public.”

That distinction — between transparent reform and opaque control — is now the fault line in American science policy. The numbers Congress approved look stable. The process beneath them does not. And the world that American research has supported for decades is watching to see what happens next.